| Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ... Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014 | 523 | 2014 |
| Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study A Chanan-Khan, KC Miller, L Musial, D Lawrence, S Padmanabhan, ... Journal of clinical oncology 24 (34), 5343-5349, 2006 | 522 | 2006 |
| Historia natural de nueva España F Hernández Universidad Nacional de México 2, 1571-1577, 1959 | 505 | 1959 |
| Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed … M Kamdar, SR Solomon, J Arnason, PB Johnston, B Glass, V Bachanova, ... The Lancet 399 (10343), 2294-2308, 2022 | 392 | 2022 |
| Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype FJ Hernandez‐Ilizaliturri, G Deeb, PL Zinzani, SA Pileri, F Malik, ... Cancer 117 (22), 5058-5066, 2011 | 383 | 2011 |
| Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of … N Reddy, FJ Hernandez‐Ilizaliturri, G Deeb, M Roth, M Vaughn, J Knight, ... British journal of haematology 140 (1), 36-45, 2008 | 314 | 2008 |
| Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and … MS Czuczman, S Olejniczak, A Gowda, A Kotowski, A Binder, H Kaur, ... Clinical Cancer Research 14 (5), 1561-1570, 2008 | 298 | 2008 |
| Historia de las plantas de Nueva España F Hernández, I Ochoterena, J Rojo | 275 | 1942 |
| Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin’s lymphoma severe combined immunodeficiency mouse model FJ Hernandez-Ilizaliturri, V Jupudy, J Ostberg, E Oflazoglu, A Huberman, ... Clinical cancer research 9 (16), 5866-5873, 2003 | 238 | 2003 |
| Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model FJ Hernandez-Ilizaliturri, N Reddy, B Holkova, E Ottman, MS Czuczman Clinical Cancer Research 11 (16), 5984-5992, 2005 | 208 | 2005 |
| Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma MS Czuczman, A Koryzna, A Mohr, C Stewart, K Donohue, L Blumenson, ... Journal of Clinical Oncology 23 (4), 694-704, 2005 | 201 | 2005 |
| Antigüedades de la nueva España F Hernández, AH de León-Portilla Historia 16, 1986 | 191 | 1986 |
| NCCN guidelines insights: B-cell lymphomas, version 3.2019: featured updates to the NCCN guidelines AD Zelenetz, LI Gordon, JS Abramson, RH Advani, NL Bartlett, PF Caimi, ... Journal of the National Comprehensive Cancer Network 17 (6), 650-661, 2019 | 166 | 2019 |
| Outcomes of patients with double-hit lymphoma who achieve first complete remission DJ Landsburg, MK Falkiewicz, J Maly, KA Blum, C Howlett, T Feldman, ... Journal of Clinical Oncology 35 (20), 2260, 2017 | 166 | 2017 |
| A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory … MS Czuczman, M Trněný, A Davies, S Rule, KM Linton, ... Clinical cancer research 23 (15), 4127-4137, 2017 | 162 | 2017 |
| Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia WG Wierda, TJ Kipps, J Dürig, L Griskevicius, S Stilgenbauer, J Mayer, ... Blood, The Journal of the American Society of Hematology 117 (24), 6450-6458, 2011 | 160 | 2011 |
| Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody DM Goldenberg, EA Rossi, R Stein, TM Cardillo, MS Czuczman, ... Blood, The Journal of the American Society of Hematology 113 (5), 1062-1070, 2009 | 157 | 2009 |
| NCCN guidelines insights: non-Hodgkin's lymphomas, version 3.2016 SM Horwitz, AD Zelenetz, LI Gordon, WG Wierda, JS Abramson, ... Journal of the National Comprehensive Cancer Network 14 (9), 1067-1079, 2016 | 151 | 2016 |
| Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression SH Olejniczak, FJ Hernandez-Ilizaliturri, JL Clements, MS Czuczman Clinical cancer research 14 (5), 1550-1560, 2008 | 151 | 2008 |
| Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines RT Hoppe, RH Advani, WZ Ai, RF Ambinder, P Aoun, CM Bello, ... Journal of the National Comprehensive Cancer Network 10 (5), 589-597, 2012 | 132 | 2012 |
